What is Gero?
Founded in 2018, Gero operates at the intersection of artificial intelligence and pharmaceutical research. The company utilizes a next-generation AI platform designed to accelerate the identification of new drug candidates targeting intricate and challenging diseases. By analyzing vast datasets and employing sophisticated machine learning algorithms, Gero aims to streamline the traditionally lengthy and costly drug discovery process, positioning itself as a key innovator in the biotech sector.
How much funding has Gero raised?
Gero has raised a total of $8.2M across 1 funding round:
Series A
$8.2M
Series A (2023): $8.2M with participation from Bulba Ventures and Melnichek Investments
Key Investors in Gero
Bulba Ventures
Bulba Ventures is an investment firm that participated in Gero's Series A funding round.
Melnichek Investments
Melnichek Investments is an investment entity that contributed to Gero's Series A financing.
What's next for Gero?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions Gero for accelerated growth and expanded research and development initiatives. This backing is expected to fuel the company's efforts to translate its AI-driven discoveries into tangible therapeutic solutions. Gero's focus on complex diseases suggests a long-term vision for impacting significant unmet medical needs, with this funding likely enabling further clinical validation and pipeline expansion.
See full Gero company page
